ZTS:NYE-Zoetis Inc. Class A

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 85.45

Change

0.00 (0.00)%

Market Cap

USD 41.45B

Volume

1.82M

Yahoo Analyst Target

USD 85.13 (-0.37%)

STA Analyst Target

USD 81.41 (-4.72%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-04-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

N/A

USD 339.78B
PFE Pfizer Inc.

N/A

USD 217.90B
NVS Novartis AG

N/A

USD 181.52B
MRK Merck & Company Inc. (new)

N/A

USD 158.41B
ABBV AbbVie Inc.

N/A

USD 146.93B
SNY Sanofi American Depositary Sha..

N/A

USD 99.76B
GSK GlaxoSmithKline PLC

N/A

USD 99.18B
AZN Astrazeneca PLC

N/A

USD 89.52B
LLY Eli Lilly and Company

N/A

USD 86.39B
BMY Bristol-Myers Squibb Company

N/A

USD 83.66B

ETFs Containing ZTS

DXG:CA Dynamic iShares Active Gl.. 9.93 % 0.91 %

N/A

CAD 0.06B
DXU:CA Dynamic iShares Active U... 9.69 % 0.89 %

N/A

CAD 0.03B
MOO VanEck Vectors Agribusine.. 7.27 % 0.54 %

N/A

USD 0.88B
IHE iShares U.S. Pharmaceutic.. 4.81 % 0.44 %

N/A

USD 0.38B
XPH SPDR S&P Pharmaceuticals 4.25 % 0.35 %

N/A

USD 0.35B
FTCS First Trust Capital Stren.. 2.32 % 0.61 %

N/A

USD 0.82B
ZUH:CA BMO Equal Weight US Healt.. 1.81 % 0.39 %

N/A

CAD 0.31B
RYH PowerShares S&P 500 Equal.. 1.72 % 0.40 %

N/A

USD 0.63B
IWP iShares Russell Midcap Gr.. 1.30 % 0.25 %

N/A

USD 8.54B
NFO PowerShares Insider Senti.. 1.23 % 0.61 %

N/A

USD 0.10B
PSET Principal Price Setters I.. 1.06 % 0.40 %

N/A

USD 0.02B
JMIN JPMorgan U.S. Minimum Vol.. 0.62 % 0.00 %

N/A

N/A
IWR iShares Russell Mid-Cap 0.58 % 0.20 %

N/A

USD 17.08B
JPME JPMorgan Diversified Retu.. 0.58 % 0.26 %

N/A

USD 63.70

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.61% 100% A+ 95% A
Dividend Return 0.35% 18% F 22% F
Total Return 18.96% 100% A+ 95% A
Trailing 12 Months  
Capital Gain 57.69% 95% A 96% A
Dividend Return 0.85% 14% F 10% F
Total Return 58.54% 95% A 96% A
Trailing 5 Years  
Capital Gain 161.24% 100% A+ 92% A-
Dividend Return 5.71% 27% F 14% F
Total Return 166.94% 100% A+ 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 22.76% 100% A+ 93% A
Dividend Return 23.62% 100% A+ 92% A-
Total Return 0.87% 27% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 19.74% 62% D- 37% F
Risk Adjusted Return 119.67% 95% A 86% B
Market Capitalization 24.45B 48% F 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.00 38% F 13% F
Price/Book Ratio 20.89 14% F 3% F
Price / Cash Flow Ratio 10.10 5% F 6% F
Price/Free Cash Flow Ratio 37.15 14% F 14% F
Management Effectiveness  
Return on Equity 48.79% 86% B 95% A
Return on Invested Capital 28.25% 95% A 91% A-
Return on Assets 10.37% 86% B 89% B+
Debt to Equity Ratio 277.75% 15% F 12% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

ZTS:NYE-Zoetis Inc. Class A

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 85.45

Change

0.00 (0.00)%

Market Cap

USD 41.45B

Volume

1.82M

Yahoo Analyst Target

USD 85.13 (-0.37%)

STA Analyst Target

USD 81.41 (-4.72%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-04-21